Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BG-71332 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BG-71332, Zanubrutinib + Sonrotoclax | EXPERIMENTAL | Participants will receive the following treatments in one of six sequences: one dose of BG-71332 with a high-fat meal, one dose of BG-71332 in a fasted state, and one dose of zanubrutinib and sonrotoclax administered together with a high-fat meal. |
| Name | Type | Description |
|---|---|---|
| BG-71332 | DRUG | Administered orally |
| Zanubrutinib | DRUG | Administered orally |
| Sonrotoclax | DRUG | Administered orally |
Inclusion Criteria: * In good health, determined by no clinically significant findings from medical history, 12-lead ECGs, vital sign measurements, and clinical laboratory evaluations as assessed by the investigator. * An absolute B-cell count of \>200 cells/μL. * Female participants must be of non...
BG-71332 is an investigational small molecule being developed by BeOne Medicines Ltd. It is a fixed-dose combination tablet containing zanubrutinib and sonrotoclax. The drug is currently in Phase 1 clinical development and has been studied in healthy volunteers.
BG-71332 is being studied for use in healthy volunteers. The Phase 1 clinical trial was designed to investigate the relative bioavailability and food effect of the fixed-dose combination tablet. It is not approved for any disease indication and remains in early clinical development.
BG-71332 is being developed by BeOne Medicines Ltd., a biopharmaceutical company. The company is publicly traded under the ticker symbol ONC. The drug is a small molecule fixed-dose combination tablet.
BG-71332 is in Phase 1 clinical development. The single completed Phase 1 trial enrolled 24 healthy adult participants in Australia. The drug is investigational and has not been approved by regulatory authorities.
BG-71332 has one completed Phase 1 clinical trial, identified as NCT07141511. The study investigated the relative bioavailability and food effect of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax in healthy adults. The trial enrolled 24 participants.
BG-71332 is a fixed-dose combination tablet that contains both zanubrutinib and sonrotoclax as its active ingredients. It is a single drug product combining these two components, rather than being the same as either drug individually.